Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc. is a recognized specialty pharmaceutical company that uses state-of-the-art, cGMP compliant facilities to develop, manufacture, and market injectable and inhalation products. Amphastar and its subsidiaries each have their own distinct focus that they skillfully bring together to meet the varied needs of the pharmaceutical industry. Its products include Enoxaparin Sodium Injection, Cortrosyn, Amphadase, Emergency Syringes in Luer-Jet, Lidocaine, Naloxone, and Phytonadione Injection.

Company Growth (employees)
Type
Public
HQ
Rancho Cucamonga, US
Founded
1996
Size (employees)
1,541 (est)
Amphastar Pharmaceuticals was founded in 1996 and is headquartered in Rancho Cucamonga, US

Amphastar Pharmaceuticals Office Locations

Amphastar Pharmaceuticals has an office in Rancho Cucamonga
Rancho Cucamonga, US (HQ)
11570 6th St

Amphastar Pharmaceuticals Financials and Metrics

Amphastar Pharmaceuticals Financials

Amphastar Pharmaceuticals's revenue was reported to be $255.2 m in FY, 2016
USD

Revenue (Q2, 2017)

65.2 m

Gross profit (Q2, 2017)

26.7 m

Gross profit margin (Q2, 2017), %

41%

Net income (Q2, 2017)

2 m

EBIT (Q2, 2017)

2.2 m

Market capitalization (13-Dec-2017)

926.2 m

Cash (30-Jun-2017)

82.5 m
Amphastar Pharmaceuticals's current market capitalization is $926.2 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

210.5 m251.5 m255.2 m

Revenue growth, %

20%1%

Cost of goods sold

159.2 m174.2 m151 m

Gross profit

51.3 m77.3 m104.2 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

49 m59.7 m56.9 m53.9 m63.9 m59.4 m68 m64.2 m56.7 m65.2 m

Cost of goods sold

34 m47.9 m43.6 m40.5 m46.3 m34.5 m36.3 m36.6 m33.8 m38.4 m

Gross profit

15 m11.8 m13.3 m13.3 m17.6 m24.9 m31.7 m27.6 m22.8 m26.7 m

Gross profit Margin, %

31%20%23%25%28%42%47%43%40%41%
USDY, 2012Y, 2013FY, 2014FY, 2015FY, 2016

Cash

50.2 m53.6 m67.8 m66.1 m72.4 m

Accounts Receivable

22.9 m33.2 m26.8 m

Inventories

118.4 m

Current Assets

198 m175.9 m184.1 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

64.1 m72.9 m68.6 m74.5 m76.8 m82.5 m

Accounts Receivable

18.6 m26.6 m21.7 m19.8 m25 m23.1 m23.1 m26.6 m25.9 m24.1 m

Inventories

106 m88.1 m84.9 m80.2 m72.4 m82.2 m88.3 m90.7 m78.1 m74.5 m

Current Assets

214.2 m215.2 m202.6 m203.9 m199.1 m173.4 m181.3 m190.2 m191.4 m193.6 m
USDFY, 2014FY, 2015FY, 2016

Net Income

(10.7 m)(2.8 m)10.5 m

Depreciation and Amortization

12 m

Accounts Receivable

1.2 m6.4 m

Inventories

9.1 m(9.7 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(1.2 m)(5.4 m)(665 k)(6.6 m)(3 m)2.5 m6.9 m3.9 m893 k

Accounts Receivable

18.6 m26.6 m21.7 m19.8 m25 m23.1 m23.1 m26.6 m25.9 m

Accounts Payable

17.8 m10 m18.9 m18.4 m12.3 m18.6 m18.8 m13.4 m19.3 m
Y, 2017

Financial Leverage

1.3 x
Show all financial metrics

Amphastar Pharmaceuticals Operating Metrics

FY, 2016

Products

19

Facilities

5
Show all operating metrics

Amphastar Pharmaceuticals Market Value History

Amphastar Pharmaceuticals Revenue Breakdown

Amphastar Pharmaceuticals Median Salaries

Source: 12 public H-1B filings from Amphastar Pharmaceuticals

Amphastar Pharmaceuticals's Web-traffic and Trends

Amphastar Pharmaceuticals Online and Social Media Presence

Amphastar Pharmaceuticals Company Life and Culture

You may also be interested in